BACKGROUND: Retinoblastoma, a curable eye tumor, is associated with poor survival in Central America (CA). To develop a retinoblastoma program in El Salvador, Guatemala, and Honduras, twinning initiatives were undertaken between local pediatric oncology centers, nonprofit foundations, St. Jude Children's Research Hospital, and the University of Tennessee Hamilton Eye Institute. PROCEDURE: The retinoblastoma program focused on developing early diagnosis programs in Honduras with national vaccination campaigns, developing treatment protocols suited to local conditions, building local networks of oncologists and ophthalmologists, training local healthcare providers, using modern donated equipment for diagnosis and treatment, and the ORBIS Cybersight consultation program and Internet meetings to further education and share expertise. Pediatric ophthalmologists and oncologists worked with foundations to treat patients locally with donated equipment and Internet consultations, or at the center in Guatemala. RESULTS: Number of patients successfully treated increased after the program was introduced. For 2000-2003 and 2004-2007, patients abandoning/refusing treatment decreased in Guatemala from 20 of 95 (21%) to 14 of 123 (11%) and in Honduras from 13 of 37 (35%) to 7 of 37 (19%). Survival in El Salvador was good and abandonment/refusal low for both periods. Of 18 patients receiving focal therapy for advanced disease, 14 have single remaining eyes. CONCLUSION: Development of the program in CA has decreased abandonment/refusal and enabled ophthalmologists at local centers to use modern equipment to provide better treatment. This approach might serve as a guide for developing other multispecialty programs. Copyright 2009 Wiley-Liss, Inc.
BACKGROUND:Retinoblastoma, a curable eye tumor, is associated with poor survival in Central America (CA). To develop a retinoblastoma program in El Salvador, Guatemala, and Honduras, twinning initiatives were undertaken between local pediatric oncology centers, nonprofit foundations, St. Jude Children's Research Hospital, and the University of Tennessee Hamilton Eye Institute. PROCEDURE: The retinoblastoma program focused on developing early diagnosis programs in Honduras with national vaccination campaigns, developing treatment protocols suited to local conditions, building local networks of oncologists and ophthalmologists, training local healthcare providers, using modern donated equipment for diagnosis and treatment, and the ORBIS Cybersight consultation program and Internet meetings to further education and share expertise. Pediatric ophthalmologists and oncologists worked with foundations to treat patients locally with donated equipment and Internet consultations, or at the center in Guatemala. RESULTS: Number of patients successfully treated increased after the program was introduced. For 2000-2003 and 2004-2007, patients abandoning/refusing treatment decreased in Guatemala from 20 of 95 (21%) to 14 of 123 (11%) and in Honduras from 13 of 37 (35%) to 7 of 37 (19%). Survival in El Salvador was good and abandonment/refusal low for both periods. Of 18 patients receiving focal therapy for advanced disease, 14 have single remaining eyes. CONCLUSION: Development of the program in CA has decreased abandonment/refusal and enabled ophthalmologists at local centers to use modern equipment to provide better treatment. This approach might serve as a guide for developing other multispecialty programs. Copyright 2009 Wiley-Liss, Inc.
Authors: Carlos A Leal-Leal; Roberto Rivera-Luna; Martha Flores-Rojo; Juan C Juárez-Echenique; Juan C Ordaz; Jorge Amador-Zarco Journal: Clin Transl Oncol Date: 2006-01 Impact factor: 3.405
Authors: Scott C Howard; Roberta Ortiz; Luis Fulgencio Baez; Ricardo Cabanas; José Barrantes; Ligia Fu; Armando Peña; Angélica Samudio; Martha Vizcaino; Carlos Rodríguez-Galindo; Ronald D Barr; Valentino Conter; Andrea Biondi; Giuseppe Masera Journal: Pediatr Blood Cancer Date: 2007-04 Impact factor: 3.167
Authors: M Bonilla; N Moreno; N Marina; G deReyes; S A Shurtleff; J R Downing; F G Behm; P L Harrison; R C Ribeiro; O Peña; W M Crist; F G Antillon Journal: J Pediatr Hematol Oncol Date: 2000 Nov-Dec Impact factor: 1.289
Authors: Christopher Leander; Ligia C Fu; Armando Peña; Scott C Howard; Carlos Rodriguez-Galindo; Judith A Wilimas; Raul C Ribeiro; Barrett Haik Journal: Pediatr Blood Cancer Date: 2007-11 Impact factor: 3.167
Authors: Lisa Ayoub; Ligia Fú; Armando Peña; Jose Manuel Sierra; Pablo Cesar Dominguez; Ching-Hon Pui; Yuri Quintana; Alicia Rodriguez; Ronald D Barr; Raul C Ribeiro; Monika L Metzger; Judy A Wilimas; Scott C Howard Journal: Pediatr Blood Cancer Date: 2007-07 Impact factor: 3.167
Authors: Carlos Rodriguez-Galindo; Mathew W Wilson; Guillermo Chantada; Ligia Fu; Ibrahim Qaddoumi; Célia Antoneli; Carlos Leal-Leal; Tarun Sharma; Margarita Barnoya; Sidnei Epelman; Louis Pizzarello; Javier R Kane; Ray Barfield; Thomas E Merchant; Leslie L Robison; A Linn Murphree; Patricia Chevez-Barrios; Michael A Dyer; Joan O'Brien; Raul C Ribeiro; John Hungerford; Eugene M Helveston; Barrett G Haik; Judith Wilimas Journal: Pediatrics Date: 2008-09 Impact factor: 7.124
Authors: Ibrahim Qaddoumi; Ibrahim Nawaiseh; Mustafa Mehyar; Bassem Razzouk; Barrett G Haik; Saamir Kharma; Imad Jaradat; Carlos Rodriguez-Galindo; Matthew W Wilson Journal: Pediatr Blood Cancer Date: 2008-08 Impact factor: 3.167
Authors: Helen Dimaras; Timothy W Corson; David Cobrinik; Abby White; Junyang Zhao; Francis L Munier; David H Abramson; Carol L Shields; Guillermo L Chantada; Festus Njuguna; Brenda L Gallie Journal: Nat Rev Dis Primers Date: 2015-08-27 Impact factor: 52.329